Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

25.17
+0.17000.68%
Volume:142.32K
Turnover:3.57M
Market Cap:5.12B
PE:-9.39
High:25.29
Open:24.84
Low:24.70
Close:25.00
52wk High:29.25
52wk Low:12.72
Shares:203.53M
Float Shares:89.02M
Volume Ratio:0.45
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6799
EPS(LYR):-2.7303
ROE:-69.35%
ROA:-41.33%
PB:5.19
PE(LYR):-9.22

Loading ...

Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares

Reuters
·
Feb 19

Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
Feb 11

Immunovant (IMVT) Gets a Buy from Oppenheimer

TIPRANKS
·
Feb 11

Immunovant Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 10

Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity

TIPRANKS
·
Feb 10

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 09

Immunovant (IMVT) Receives a Buy from J.P. Morgan

TIPRANKS
·
Feb 09

Immunovant price target raised to $44 from $41 at Guggenheim

TIPRANKS
·
Feb 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)

TIPRANKS
·
Feb 09

Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position

Stock Track
·
Feb 06

Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position

Stock Track
·
Feb 06

Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
Feb 06

Immunovant Q3 net loss smaller than expected

Reuters
·
Feb 06

Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate

Benzinga
·
Feb 06

BRIEF-Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million

Reuters
·
Feb 06

Immunovant Q3 Basic EPS USD -0.61

THOMSON REUTERS
·
Feb 06

Immunovant Q3 Net Income USD -110.635 Million VS. Ibes Estimate USD -125.1 Million

THOMSON REUTERS
·
Feb 06

Immunovant Q3 Operating Expenses USD 114.362 Million

THOMSON REUTERS
·
Feb 06

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

THOMSON REUTERS
·
Feb 06

Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish

Earnings Agent
·
Jan 30